Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer

Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864 3. Histologically confirmed HER2 positive breast cancer 1. Any Estrogen Receptor/Progesterone Receptor status is allowed. 2. HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \> 2.0 or \> 6 total HER2 gene copies per cell. 4. High-risk disease defined as one of the following: 1. Any residual invasive carcinoma in the breast or axill…